The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 2, 2004, Pages 492-501

  Nieman, Marvin T ^a,b   Warnock, Mark ^a,b   Hasan, Ahmed A K ^a   Mahdi, Fakhri ^b   Lucchesi, Benedict R ^b   Brown, Nancy J ^c   Murphey, Laine J ^c   Schmaier, Alvin H ^a,b,d  

^a Thromgen Inc   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ARGINYLPROLYLPROLYLGLYCYLPHENYLALANINE DERIVATIVE; BETA ALANYLLYSYL 2 LYSYL 4 (DEXTRO ARGININE OCTAHYDROINDOLE 2 CARBOXYLIC ACID PROLYLGLYCYLPHENYLALANINE); BLOOD CLOTTING FACTOR 7A INHIBITOR; BRADYKININ; DEXTRO ARGININE OCTAHYDROINDOLE 2 CARBOXYLIC ACID PROLYLGLYCLYLPHENYLALANINE; DIPEPTIDYL CARBOXYPEPTIDASE; MAP4 TH146; N 3 AMINO 1 [[[(PHENYLMETHYL)AMINO]CARBONYL]PROPYL] ALPHA [[[[[1 (2,6 DICHLOROPHENYL)METHYL] 3 (1 PYRROLIDINYLMETHYL) 1H INDAZOL 6 YL]AMINO]CARBONYL]AMINO] 3,4 DIFLUOROBENZENEPROPANAMIDE; PROTEIN; PROTEIN MAP4; PROTEIN TH146; PROTEINASE ACTIVATED RECEPTOR 1 ACTIVATION ANTAGONIST; PROTEINASE ACTIVATED RECEPTOR AGONIST; RWJ 58259; SYNTHETIC PEPTIDE; TH 146; THROMBIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; FIBROBLAST; INHIBITION KINETICS; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; THROMBOSIS PREVENTION;

ANIMALS; BLEEDING TIME; BLOOD PRESSURE; BRADYKININ; DISEASE MODELS, ANIMAL; FACTOR VIIA; HUMANS; MICE; PEPTIDE FRAGMENTS; PEPTIDES; PLATELET AGGREGATION; RECEPTOR, PAR-1; THROMBIN; THROMBOSIS;

EID: 6344247582     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.069229     Document Type: Article

References (33)

1. Ayala YM, Cantwell AM, Rose T, Bush LA, Arosio D, and DiCera E (2001) Molecular mapping of thrombin-receptor interactions. Proteins 45:107-116.
2. Bieth JG (1984) In vivo significance of kinetic constants of protein proteinase inhibitors. Biochem Med 222:209-223.
3. Cleary DB, Ehringer WD, and Maurer MC (2003) Establishing the inhibitory effects of bradykinin on thrombin. Arch Biochem Biophys 410:96-106.
4. Cleary DB, Trumbo TA, and Maurer MC (2002) Protease-activated receptor 4-like peptides bind to thrombin through an optimized interaction with the enzyme active site surface. Arch Biochem Biophys 403:179-188.
5. Cook JJ, Sitko GR, Bednar B, Condra C, Mellott MJ, Feng DM, Nutt RF, Shafer JA, Gould RJ, and Connolly TM (1995) Molecular and cellular cardiology: an antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 91:2961-2971.
6. Cui J, Eitzman DT, Westrick RJ, Christie PD, Xu ZJ, Yang AY, Purkayastha AA, Yang TL, Metz AL, Gallagher KP, et al. (2000) Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood 96:4222-4226.
7. Derian CK, Damiano BP, Addo MF, Darrow AL, D'Andrea MR, Nedelman M, Zhang HC, Maryanoff BE, and Andrade-Gordon P (2003) Blockage of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 304:855-861.
8. Eitzman DT, Westrick RJ, Nabel EG, and Ginsburg D (2000) Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 95:577-580.
9. 2+ requirements for phospholipase C activation. Mol Pharmacol 35:195-204.
10. Hanson SR and Harker LA (1988) Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 85:3184-3188.
11. Kasan AAK, Amenta S, and Schmaier AH (1996) Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of α-thrombin-induced platelet activation. Circulation 94:517-528.
12. Hasan AAK, Cines DB, Zhang J, and Schmaier AH (1994) The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain. J Biol Chem 269:31822-31830.
13. Hasan AAK, Rebello SS, Smith E, Srikanth S, Werns S, Driscoll E, Faul J, Brenner D, Normolle D, Lucchesi BR, et al. (1999) Thrombostatin inhibits induced canine coronary thrombosis. Thromb Haemostasis 82:1182-1187.
14. Hasan AAK, Schmaier AH, Warnock M, Normolle D, Driscoll E, Lucchesi BR, and Werns SW (2001a) Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries. Thromb Haemostasis 86:1296-1304.
15. Hasan AAK, Warnock M, Nieman M, Srikanth S, Mahdi F, Krishnan R, Tulinsky A, and Schmaier AH (2003) Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin. Am J Physiol 285:H183-H193.
16. Hasan AAK, Warnock M, Srikanth S, and Schmaier AH (2001b) Developing peptide inhibitors to thrombin activation of platelets from bradykinin analogs. Thromb Res 104:451-465.
17. Kato Y, Kita Y, Hirasawa-Taniyama Y, Nishio M, Mihara K, Ito K, Yamanaka T, Seki J, Miyata S, and Mutoh S (2003) Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol 473:163-169.
18. Mahdi F, Rehemtulla A, Van Nostrand WE, Bajaj SP, and Schmaier AH (2000) Protease nexin-2/amyloid β-protein precursor regulates factor VIIa and factor VIIa-tissue factor complex. Thromb Res 99:267-276.
19. Malave HA, Murphey LJ, Vaughan DE, Biaggioni I, and Brown NJ (2003) RPPGF inhibits alpha-thrombin and gamma-thrombin-induced platelet aggregation in the human vasculature. Arterioscler Thromb Vasc Biol 23:P106.
20. Meloni FJ and Schmaier AH (1991) Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. J Biol Chem 266: 6786-6794.
21. Murphey LJ, Hachey DL, Oates JA, Morrow JD, and Brown NJ (2000) Metabolism of bradykinin in vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite. J Pharmacol Exp Ther 294:263-269.
22. Murphey LJ, Hachey DL, Vaughan DE, Brown NJ, and Morrow JD (2001) Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay. Anal Biochem 292:87-93.
23. Niewiarowski S, Kirby EP, Brudzynski TM, and Stocker K (1979) Thrombocytin, a serine protease from Bothrops atrox venom. 2. Interaction with platelets and plasma-clotting factors. Biochemistry 18:3570-3577.
24. Prieto AR, Ma H, Huang R, Khan G, Schwartz KA, Hage-Korban EF, Schmaier AH, Davis JM, Hasan AAK, and Abela GS (2002) Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury. Cardiovas Res 53:984-992.
25. Puri R, Zhou F, Hu CJ, Colman RF, and Colman RW (1991) High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets. Blood 77:500-507.
26. Rowland M and Tozer T (1989) Clinical Pharmacokinetics: Concepts and Application, 2nd ed, Lea & Febiger, Philadelphia.
27. Santos BF, Serrano SM, Kuliopulos A, and Niewiarowski S (2000) Interaction of viper venom serine peptidases with thrombin receptors on human platelets. FEBS Lett 477:199-202.
28. Schmaier AH, Dahl LD, Hasan AAK, Cines DB, Bauer KA, and Van Nostrand WE (1995) Factor IXa inhibition by protease nexin-2/amyloid β-protein precursor on phospholipid vesicles and cell membranes. Biochemistry 34:1171-1178.
29. Schmaier AH, Pagan-Ramos E, Warnock M, Krijanovski Y, Hasan AAK, and Nieman MT (2003) Arg-Pro-Pro-Gly-Phe binds to the exodomain of human protease activated receptor 4 (PAR4) to prevent thrombin proteolysis and platelet activation (Abstract). Blood 102 (Suppl 1):776a-777a.
30. Stewart JM, Gera L, York EJ, Chan DC, and Bunn P (1999) Bradykinin antagonists: present progress and future prospects. Immunopharmacology 43:155-161.
31. Stewart JM, Gera L, York EJ, Chan DC, Whalley EJ, Bunn PA Jr, and Vavrek RJ (2001) Metabolism-resistant bradykinin antagonists: development and applications. Biol Chem 382:37-41.
32. Weiss EJ, Hamilton JR, Lease KE, and Coughlin SR (2002) Protection against thrombosis in mice lacking PARS. Blood 100:3240-3244.
33. Whitesall SE, Hoff JB, Vollmer AP, and D'Alecy LG (2004) Comparison of simultaneous measurement of mouse systolic arterial blood pressure by radiotelemetry and tail-cuff methods. Am J Physiol 286:H2408-H2415.